{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016832","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.129839+00:00","generated_at":"2026-05-21T08:13:08.513695+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M","bullets":["Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.","Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.","Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.","Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.","Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016832","json":"https://secwatch.observer/filing/0001437749-25-016832.json","markdown":"https://secwatch.observer/filing/0001437749-25-016832.md","text":"https://secwatch.observer/filing/0001437749-25-016832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/0001437749-25-016832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/aytu20250213_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:13:08.513695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}